Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SCYNEXIS INCSCYX · Entity 7194 | Director · Chief Executive Officer | April 01, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SCYNEXIS INC
Report date April 01, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,357,126 |
Reported balance
After 2026-04-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-01 · Purchase · Acquired 108,695 · Balance 1,357,126 F1: On March 30, 2026, the Issuer entered into a Securities Purchase Agreement with certain accredited investors, including the Reporting Person (the "Purchase Agreement"). Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on April 1, 2026, 108,695 shares of the Issuer's common stock (the "Shares") and accompanying warrants to purchase up to 108,695 shares of common stock of the Issuer (the "Common Warrants"). The combined purchase price for each Share and accompanying Common Warrant was $0.92. F2: Includes 4,000 shares of common stock acquired under the 2014 Employee Stock Purchase Plan of the Issuer on March 5, 2026. |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.20 | Direct | 108,695 |
Reported balance
After 2026-04-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-01 · Purchase · Acquired 108,695 · Balance 108,695 F1: On March 30, 2026, the Issuer entered into a Securities Purchase Agreement with certain accredited investors, including the Reporting Person (the "Purchase Agreement"). Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on April 1, 2026, 108,695 shares of the Issuer's common stock (the "Shares") and accompanying warrants to purchase up to 108,695 shares of common stock of the Issuer (the "Common Warrants"). The combined purchase price for each Share and accompanying Common Warrant was $0.92. F3: The Common Warrants will be exercisable beginning on the effective date of the stockholder approval relating to the proposed increase in the Issuer's authorized shares of common stock. F4: The Common Warrants will expire on the earlier of (i) the fifth (5th) anniversary of its original issue date and (ii) the thirtieth (30th) day after the Issuer publicly releases topline data at Week 48 from the Issuer's Phase 2 proof-ofconcept clinical study evaluating SCY-770 in patients with autosomal dominant polycystic kidney disease. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 30, 2026, the Issuer entered into a Securities Purchase Agreement with certain accredited investors, including the Reporting Person (the "Purchase Agreement"). Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on April 1, 2026, 108,695 shares of the Issuer's common stock (the "Shares") and accompanying warrants to purchase up to 108,695 shares of common stock of the Issuer (the "Common Warrants"). The combined purchase price for each Share and accompanying Common Warrant was $0.92.
F2: Includes 4,000 shares of common stock acquired under the 2014 Employee Stock Purchase Plan of the Issuer on March 5, 2026.
F3: The Common Warrants will be exercisable beginning on the effective date of the stockholder approval relating to the proposed increase in the Issuer's authorized shares of common stock.
F4: The Common Warrants will expire on the earlier of (i) the fifth (5th) anniversary of its original issue date and (ii) the thirtieth (30th) day after the Issuer publicly releases topline data at Week 48 from the Issuer's Phase 2 proof-ofconcept clinical study evaluating SCY-770 in patients with autosomal dominant polycystic kidney disease.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 2, 2026 12:01 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseWarrant to Purchase Common Stock · Derivative | 108,695 | Not disclosed Strike: $1.20 | Not disclosed |
DisclosureSEC source: 0001644071-26-000002 · ownership.xml · derivative · entry 2 Angulo Gonzalez David · CIK 0001644071 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,695 Underlying: Common Stock · 108,695 shares Expires not disclosed F1 · price: On March 30, 2026, the Issuer entered into a Securities Purchase Agreement with certain accredited investors, including the Reporting Person (the "Purchase Agreement"). Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on April 1, 2026, 108,695 shares of the Issuer's common stock (the "Shares") and accompanying warrants to purchase up to 108,695 shares of common stock of the Issuer (the "Common Warrants"). The combined purchase price for each Share and accompanying Common Warrant was $0.92. F3 · derivative.exercise_date: The Common Warrants will be exercisable beginning on the effective date of the stockholder approval relating to the proposed increase in the Issuer's authorized shares of common stock. F4 · derivative.expiration_date: The Common Warrants will expire on the earlier of (i) the fifth (5th) anniversary of its original issue date and (ii) the thirtieth (30th) day after the Issuer publicly releases topline data at Week 48 from the Issuer's Phase 2 proof-ofconcept clinical study evaluating SCY-770 in patients with autosomal dominant polycystic kidney disease. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 12:01 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 108,695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001644071-26-000002 · ownership.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,357,126 F1 · price: On March 30, 2026, the Issuer entered into a Securities Purchase Agreement with certain accredited investors, including the Reporting Person (the "Purchase Agreement"). Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Person in a private placement, which closed on April 1, 2026, 108,695 shares of the Issuer's common stock (the "Shares") and accompanying warrants to purchase up to 108,695 shares of common stock of the Issuer (the "Common Warrants"). The combined purchase price for each Share and accompanying Common Warrant was $0.92. F2 · balance_after: Includes 4,000 shares of common stock acquired under the 2014 Employee Stock Purchase Plan of the Issuer on March 5, 2026. Read SEC document |
| January 29, 2026 Filed Feb 2, 2026 21:01 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 391,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001178253-26-000003 · ownership.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,244,431 F1 · shares: Represents restricted stock units that vest one third per year over three years as measured from February 28, 2026. Read SEC document |
| October 17, 2025 Filed Oct 21, 2025 12:00 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 32,500 | $0.76 | $24,700.00 |
DisclosureSEC source: 0001178253-25-000007 · ownership.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 853,098 F1 · balance_after: Includes 4,000 shares of common stock acquired under the 2014 Employee Stock Purchase Plan on September 5, 2025. Read SEC document |
| April 09, 2025 Filed Apr 10, 2025 12:02 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 23,000 | $0.84 | $19,320.00 |
DisclosureSEC source: 0000950170-25-052675 · ownership.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 816,598 F1 · balance_after: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8384 to $0.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| March 20, 2025 Filed Mar 20, 2025 23:39 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 13,800 | $1.05 | $14,490.00 |
DisclosureSEC source: 0000950170-25-042838 · ownership.xml · nonDerivative · entry 2 Angulo Gonzalez David · CIK 0001644071 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 793,598 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.05 to $1.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| March 19, 2025 Filed Mar 20, 2025 23:39 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 5,000 | $1.07 | $5,350.00 |
DisclosureSEC source: 0000950170-25-042838 · ownership.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 779,798 F1 · balance_after: Includes 4,000 shares of common stock acquired under the 2014 Employee Stock Purchase Plan on March 5, 2025. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:01 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantEmployee Stock Option (Right to Buy) · Derivative | 394,391 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0000950170-25-009170 · ownership.xml · derivative · entry 2 Angulo Gonzalez David · CIK 0001644071 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 394,391 Underlying: Common Stock · 394,391 shares Expires 2035-01-22 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly for 48 months as measured from January 23, 2025. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:01 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 262,927 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-009170 · ownership.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 770,798 F1 · shares: Represents restricted stock units that vest one third per year over three years as measured from February 28, 2025. Read SEC document |
| September 12, 2024 Filed Sep 16, 2024 12:00 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 20,000 | $1.37 | $27,400.00 |
DisclosureSEC source: 0000950170-24-106610 · ownership.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 507,871 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.35 to $1.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · balance_after: Includes 8,000 shares of common stock acquired under the 2014 Employee Stock Purchase Plan on March 5, 2024 (4,000 shares) and September 5, 2024 (4,000 shares). Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:03 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantEmployee Stock Option (Right to Buy) · Derivative | 431,030 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0000950170-24-008808 · ownership.xml · derivative · entry 2 Angulo Gonzalez David · CIK 0001644071 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,030 Underlying: Common Stock · 431,030 shares Expires 2034-01-25 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly for 48 months as measured from February 15, 2024. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:03 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 290,590 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-008808 · ownership.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 479,871 F1 · shares: Represents restricted stock units that vest one third per year over three years as measured from February 15, 2024. F2 · balance_after: Includes 4,100 shares of common stock acquired under the 2014 Employee Stock Purchase Plan in March 2023 (100 shares) and September 2023 (4,000 shares). Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 21:01 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantEmployee Stock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-23-000155 · doc4.xml · derivative · entry 2 Angulo Gonzalez David · CIK 0001644071 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2032-12-31 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant. Read SEC document |
| January 01, 2023 Filed Jan 3, 2023 21:01 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-000155 · doc4.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,181 F1 · shares: Represents restricted stock units that vest one third per year over three years on the anniversary of the date of grant. F2 · balance_after: Includes 200 shares of common stock acquired under the 2014 Employee Stock Purchase Plan in March 2022 (100 shares) and September 2022 (100 shares). Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:11 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001209191-22-007727 · doc4.xml · derivative · entry 2 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2032-02-03 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 21:11 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 51,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007727 · doc4.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,981 F1 · shares: Represents restricted stock units that vest 50% per year over two years on the anniversary of the date of grant. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 21:00 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001209191-21-006715 · doc4.xml · derivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2031-01-28 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 14:00 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock Warrant · Derivative | 800 | Not disclosed Strike: $8.25 | Not disclosed |
DisclosureSEC source: 0001209191-20-064953 · doc4.xml · derivative · entry 3 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock · 800 shares Expires 2024-06-21 F1 · price: Reflects the purchase on December 21, 2020 of 1,600 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 14:00 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock Warrant · Derivative | 800 | Not disclosed Strike: $7.33 | Not disclosed |
DisclosureSEC source: 0001209191-20-064953 · doc4.xml · derivative · entry 2 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock · 800 shares Expires 2021-12-21 F1 · price: Reflects the purchase on December 21, 2020 of 1,600 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 14:00 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 1,600 | $6.25 | $10,000.00 |
DisclosureSEC source: 0001209191-20-064953 · doc4.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,780 F1 · price: Reflects the purchase on December 21, 2020 of 1,600 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $6.25 per share of common stock and accompanying warrants to purchase 0.50 of a share of common stock (Series 1 warrant) and 0.50 of a share of common stock (Series 2 warrant). Read SEC document |
| November 25, 2020 Filed Dec 5, 2020 01:57 UTC | SCYNEXIS INC SCYX · Entity 7194 | Tax withholdingCommon Stock | 4,323 | $6.81 | $29,439.63 |
DisclosureSEC source: 0001209191-20-061876 · doc4.xml · nonDerivative · entry 2 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,180 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations that arose in connection with a vesting event from a restricted stock unit award. F2 · balance_after: Includes 200 shares acquired in 2020 by the reporting person under the Issuer's 2014 Employee Stock Purchase Plan: 100 shares on March 5, 2020 and 100 shares on September 5, 2020. Read SEC document |
| February 15, 2020 Filed Dec 5, 2020 01:57 UTC | SCYNEXIS INC SCYX · Entity 7194 | Tax withholdingCommon Stock | 1,175 | $9.80 | $11,515.00 |
DisclosureSEC source: 0001209191-20-061876 · doc4.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,303 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations that arose in connection with a vesting event from a restricted stock unit award. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 21:03 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001209191-20-006269 · doc4.xml · derivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2030-01-30 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:51 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001209191-19-011123 · doc4.xml · derivative · entry 2 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-02-14 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:51 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011123 · doc4.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,790 F1 · shares: Represents restricted stock units that vest 25% per year over four years. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 16:28 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon stock | 12,000 | $0.50 | $5,950.80 |
DisclosureSEC source: 0001209191-19-000037 · doc4.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,790 Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 13:09 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 7,000 | $1.27 | $8,890.00 |
DisclosureSEC source: 0001209191-18-050184 · doc4.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,790 Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 12:10 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 6,000 | $1.36 | $8,160.00 |
DisclosureSEC source: 0001209191-18-022265 · doc4.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,790 Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 20:43 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 7,000 | $1.39 | $9,730.00 |
DisclosureSEC source: 0001209191-18-018877 · doc4.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,790 Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 12:48 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 6,655 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0001209191-18-018705 · doc4.xml · derivative · entry 3 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,655 Underlying: Common Stock · 6,655 shares Expires 2023-03-08 F1 · price: Reflects the purchase on March 8, 2018, of 14,790 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant). Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 12:48 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock Warrant (right to buy) · Derivative | 11,092 | Not disclosed Strike: $1.85 | Not disclosed |
DisclosureSEC source: 0001209191-18-018705 · doc4.xml · derivative · entry 2 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,092 Underlying: Common Stock · 11,092 shares Expires 2019-03-14 F1 · price: Reflects the purchase on March 8, 2018, of 14,790 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant). Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 12:48 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 14,790 | $1.69 | $24,995.10 |
DisclosureSEC source: 0001209191-18-018705 · doc4.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,790 F1 · price: Reflects the purchase on March 8, 2018, of 14,790 shares of the issuer's common stock, par value $0.001 per share, at a public offering price of $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant). Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 22:06 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.69 | $0.00 |
DisclosureSEC source: 0001209191-18-009636 · doc4.xml · derivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-02-08 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly for 48 months as measured from the date of grant. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 20:29 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 10,000 | $1.55 | $15,500.00 |
DisclosureSEC source: 0001178253-17-000017 · wf-form4_150274201826748.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Read SEC document |
| May 12, 2017 Filed May 15, 2017 12:17 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 15,000 | $1.70 | $25,500.00 |
DisclosureSEC source: 0001178253-17-000008 · wf-form4_149485063942281.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Read SEC document |
| January 31, 2017 Filed Feb 2, 2017 19:23 UTC | SCYNEXIS INC SCYX · Entity 7194 | GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $3.02 | $0.00 |
DisclosureSEC source: 0001628280-17-000754 · wf-form4_148606338202189.xml · derivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2027-01-31 F1 · derivative.exercise_date: 2.08% of the shares subject to the option vest monthly for 48 months as measured from the date of grant. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 11:44 UTC | SCYNEXIS INC SCYX · Entity 7194 | PurchaseCommon Stock | 4,000 | $3.25 | $13,000.00 |
DisclosureSEC source: 0001628280-16-022084 · wf-form4_148214783049485.xml · nonDerivative · entry 1 Angulo Gonzalez David · CIK 0001644071 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.